The Hercules Trial: NCT04411641
Patients with non-relapsing secondary progressive multiple sclerosis are encouraged to take a 2-minute pre-screener to see if they may qualify for the Hercules Trial.
- Secondary Progressive MS, Non-Relapsing (nrSPMS)
- ages 18 to 60 years
The Hercules Trial is a Phase III clinical trial designed to test how well the trial drug works and whether it is safe. The trial drug will be compared to placebo (a tablet that looks the same as the trial drug but has no therapeutic effect). The main effect that is being tested is whether the trial drug delays disability progression in patients diagnosed with non-relapsing secondary progressive multiple sclerosis (nrSPMS). Patients will be randomly selected to receive the trial drug or placebo. Patients are twice as likely to receive the trial drug vs placebo. The trial drug is being compared to placebo because approved treatments specifically for non-relapsing SPMS (nrSPMS) are not available in all countries or covered by insurance in all patients.
Additional goals of the trial will be to test the effect of the trial drug on disability progression, magnetic resonance imaging (MRI) lesions, the ability to learn and process information, and quality of life, as well as the safety and tolerability of the trial medication.
Those who qualify to participate in clinical trials may receive medical care and medication at no cost to the patient. People who participate in clinical trials aid others with the same condition by helping the scientific community find new treatment options for diseases such as multiple sclerosis.